Welcome to our dedicated page for TREACE MEDICAL CONCEPTS SEC filings (Ticker: TMCI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Treace Medical Concepts, Inc. filings document the regulatory disclosures of a medical technology company focused on devices for bunion and related midfoot surgery. Its 8-K reports cover operating results, preliminary unaudited financial information, Regulation FD investor materials, press-release exhibits and Inline XBRL cover data.
The company’s SEC record also includes disclosures on material financing arrangements, including term loan and revolving loan agreements, as well as officer departures, board changes and committee matters. Proxy materials address annual meeting procedures, director elections, executive compensation, equity awards and corporate governance for the Delaware corporation.
TREACE MEDICAL CONCEPTS, INC. (TMCI) CEO and director John T. Treace reported open‑market purchases of a total of 55,944 shares of common stock on August 20, 21 and 24, 2026 at weighted average prices of $4.44, $4.35 and $4.34 per share, respectively. The filing also reports several large indirect common stock holdings held by his spouse and in various trusts, for which he disclaims beneficial ownership, and notes that his reported holdings include 542,784 restricted stock units. The Rule 10b5‑1 checkbox is not marked, indicating these purchases were not reported as made under a trading plan.
Treace Medical Concepts, Inc. has a significant shareholder position reported by Armistice Capital, LLC and Steven Boyd, who together are listed as reporting persons for the company’s common stock. They report beneficial ownership of 6,364,000 shares of Treace Medical Concepts common stock, representing 9.79% of the outstanding class as of the reporting date.
The shares are held directly by Armistice Capital Master Fund Ltd., for which Armistice Capital acts as investment manager under an Investment Management Agreement. Armistice Capital and Steven Boyd are reported as having shared voting and dispositive power over 6,364,000 shares and no sole voting or dispositive power. The Master Fund is stated to have the right to receive dividends and sale proceeds from these securities, while Armistice Capital and Mr. Boyd may be deemed to beneficially own the position through their management roles.
TREACE MEDICAL CONCEPTS, INC. reporting person Sean F. Scanlan, Chief Innovation Officer, reported a Form 4 transaction involving 9,814 shares of common stock delivered or withheld for payment of exercise price or tax liability. Following this disposition, he directly holds 679,863 shares of common stock, which includes 463,167 restricted stock units and reflects a transfer of 15,000 shares to a former spouse pursuant to a domestic relations order.
Treace Medical Concepts, Inc. reported that its Chief Executive Officer, John T. Treace, filed an amended Schedule 13G reflecting his ownership in the company’s common stock as of June 30, 2026. Based on 64,976,624 shares of common stock outstanding, he may be deemed the beneficial owner of 12,530,959 shares, representing 19.2% of the class.
The position includes shares held directly by John T. Treace, multiple family trusts for which he or his spouse serve as trustee or co-trustee, his spouse’s holdings, and 401,175 shares underlying stock options that are currently exercisable or will be exercisable within 60 days of June 30, 2026. He has 9,045,893 shares with sole voting and dispositive power and 3,485,066 shares with shared voting and dispositive power.
TREACE MEDICAL CONCEPTS, INC. reported that Chief Financial Officer Mark Hair had 37,102 shares of common stock withheld or delivered on August 9, 2026 to satisfy exercise price or tax liability. Following this code F disposition, he directly holds 914,900 shares of common stock, including 717,604 restricted stock units.
TREACE MEDICAL CONCEPTS, INC. reported that officer Scot Michael Elder, Chief Legal & Compliance Officer and Corporate Secretary, had 16,253 shares of common stock disposed of in a code F transaction, representing shares delivered or withheld for payment of an exercise price or tax liability. Following this transaction, Elder directly held 778,683 common shares, which the company notes include 590,697 restricted stock units.
Treace Medical Concepts, Inc. reported second quarter 2026 revenue of $45.4 million, a 4% decline from $47.4 million a year earlier, with gross margin of 78.5%. Net loss was $15.9 million, or $0.24 per share, slightly better than $17.4 million, or $0.28 per share, in 2025. Adjusted EBITDA was a loss of $3.5 million, essentially flat year over year.
Total operating expenses fell 8% to $50.6 million, helping reduce year‑to‑date cash usage by 57% or $3.6 million. Cash, cash equivalents and marketable securities were $45.6 million as of June 30, 2026, and an existing credit facility provides up to $115 million of additional liquidity, subject to conditions. The company raised its 2026 revenue outlook to $204–$212 million, representing a 4% to 0% decline versus 2025, and now expects an Adjusted EBITDA loss of $3.0–$5.0 million, compared with a $3.9 million loss in 2025. Management highlighted growing adoption of its expanded bunion portfolio and new product launches including the SuperBite Compression Screw and HyperPlate XM systems.
BlackRock, Inc. filed an amended Schedule 13G reporting its beneficial ownership of common stock of Treace Medical Concepts, Inc. BlackRock reported beneficial ownership of 959,320 shares, representing 1.5% of the outstanding common stock.
BlackRock reported sole voting power and sole dispositive power over all 959,320 shares, with no shared voting or dispositive power. Various underlying persons may have rights to dividends or sale proceeds, but no single person has an interest exceeding five percent of Treace’s outstanding common shares.
Treace Medical Concepts Chief Executive Officer John T. Treace reported open-market share purchases and corrected an earlier reporting error. On June 10 he bought 14,715 shares of common stock at a weighted average price of $4.0240 per share, and on June 11 he bought 9,891 shares at a weighted average price of $4.0423 per share.
The amendment states the original Form 4 had misreported these purchases as 29,430 and 22,887 shares, respectively, and is being corrected for this administrative error. After these transactions, he directly holds 7,348,439 common shares, which includes 542,784 restricted stock units, and also reports indirect holdings through various trusts and his spouse, while disclaiming beneficial ownership of certain spouse- and trust-held shares.